

CLEAN VERSION OF EACH REPLACEMENT PARAGRAPH/SECTION/CLAIM AND
INSTRUCTIONS FOR ENTRY

IN THE SPECIFICATION:

A1
As a result of these procedures, the disease specific markers namely apolipoprotein A-IV precursor proteins having a molecular weight of about 1311.7061 daltons and having a sequence identified as SEQ ID NO: 1, apolipoprotein ion having a molecular weight of about 1287.6657 daltons and a sequence identified as SEQ ID NO: 2, and apolipoprotein ion having a molecular weight of about 1199 daltons having a sequence identified as SEQ ID NO: 3 related to Insulin Resistance were found.

IN THE CLAIMS:

AA
B1
C6
Claim 1. A biopolymer marker selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof useful in indicating at least one particular disease state.

A3
Claim 18. A kit for diagnosing, determining risk-assessment, and identifying therapeutic avenues related to a disease state comprising:

at least one biochemical material which is capable of specifically binding with a biomolecule which includes at least one biopolymer marker selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or analyte thereof related to said disease state; and means for determining binding between said biochemical material and said biomolecule;

A3 cont'd
whereby at least one analysis to determine a presence of a marker, analyte thereof, or a biochemical material specific thereto, is carried out on a sample.

A4
Claim 29. Polyclonal antibodies produced against a marker sequence ID selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof in at least one animal host.

Claim 30. An antibody that specifically binds a biopolymer including a marker selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof.

Claim 33. A process for identifying therapeutic avenues related to a disease state comprising:

A5
conducting an analysis as provided by the kit of claim 18; and
interacting with a biopolymer selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof;
whereby therapeutic avenues are developed.

Claim 34. The process for identifying therapeutic avenues related to a disease state in accordance with claim 33, wherein said therapeutic avenues regulate the presence or absence of the biopolymer selected from the group having a sequence identified as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or at least one analyte thereof.